AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04203771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of mandibular third molars at baseline
Description: Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
Study NCT04297384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study NCT04723524 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine
Description: Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
Study NCT04723524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
Study NCT01840176 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: McCall culdoplasty
Description: The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
Study NCT00003207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT00003207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSC 833
Study NCT04284007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone with perineural levobupivacaine
Description: Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
Study NCT04167761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue
Study NCT04203771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
Study NCT02007083 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral laminotomy (BL)
Study NCT02007083 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral laminotomy with crossover (UL)
Study NCT04203771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
Study NCT02007083 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinous Process Osteotomy (SPO)
Study NCT03949387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Cycling Exercise
Description: FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
Study NCT03949387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Leg Cycling
Description: Passive leg cycling will not involve electrical stimulation
Study NCT01257217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1
Description: Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
Study NCT01257217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study NCT01257217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acri.LISA® 366D IOL
Description: Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
Study NCT01257217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acri.LISA® 466TD Toric IOL
Description: Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study NCT05316636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrational forces
Study NCT02300077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Escalating dose of methadone up to .3mg/kg.
Study NCT05316636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with clear aligners
Study NCT03907579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inflatable colon educational module
Description: Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
Study NCT02300077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Intra-operative administration of opioids, other than methadone)
Description: Intra-operative administration of opioids, other than methadone
Study NCT02991950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parnaparin Sodium
Description: Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
Study NCT05316636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with clear aligners
Study NCT03407222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text messages
Description: Text messages which encourage the increment of daily step count
Study NCT03800901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuing Medical Education
Description: CME or ABIM MOC credits
Study NCT03800901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality IQ Patient Simulations
Description: Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control.
Study NCT03800901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality IQ Patient Simulations
Description: Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control.
Study NCT01158534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT01158534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given subcutaneously
Study NCT01158534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01158534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01158534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT01158534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study NCT01158534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01158534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01817946 — intervention group
Intervention type: OTHER
Intervention: Genetic Testing
Description: Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
Study NCT04526457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Randomized to standard of care with lipid testing only.
Study NCT04526457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetic Testing
Description: Randomized to genetic testing.
Study NCT03564067 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Soterix Medical tDCS mini-Clinical Trials system (mini-CT)
Description: Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
Study NCT03564067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized CBT (cCBT)
Description: Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
Study NCT03509480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Curettage for benign bone lesion
Description: Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
Study NCT03847818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin
Description: Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles
Study NCT00701740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral isotretinoin and Mexoryl SX / XL
Description: 20mg, 3/week,continuously for three months
Study NCT00701740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexoryl XL / SX
Description: 11 subjects used only the same moisturizer and SPF 60 sunscreen
Study NCT02731040 — intervention group
Intervention type: DRUG
Intervention: Bisphosphonate
Study NCT02457351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roniciclib (BAY 1000394)
Description: Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose
Study NCT02457351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (Sporanox)
Description: Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
Study NCT04201769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron
Description: NEPA is adiministered 60 minutes before chemotherapy, on day 1
Study NCT04201769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netupitant/Palonosetron
Description: NEPA is adiministered 60 minutes before chemotherapy, on day 1
Study NCT04201769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm
Study NCT04201769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm
Study NCT02286115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-Stress Interview
Description: A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
Study NCT03955107 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring System
Description: Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
Study NCT03677089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 ECHO Autism telehealth clinics
Description: Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
Study NCT00069082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide (Zucapsaicin)
Description: Nasal Solution 0.01%
Study NCT00069082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Nasal Solution 10%
Study NCT02433210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELISIO-15H
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
Study NCT02433210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revaclear
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
Study NCT02433210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflux
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
Study NCT03135028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 400 mg (2 × 200 mg tablets) orally twice daily
Study NCT03135028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
Study NCT03135028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (> 60 years of age) of each 28-day post-remission cycle
Study NCT02521051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Study NCT02521051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT03481517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
Study NCT00755235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression care management by secure messaging
Description: Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
Study NCT03367780 — intervention group
Intervention type: DEVICE
Intervention: PSMA PET/CT-scan
Description: PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
Study NCT01665404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Multiple doses of fluvoxamine
Study NCT01665404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Single dose of RO4917523
Study NCT03620981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Drug: 1 tablet /day Once daily for 10 weeks
Study NCT03654989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil iontophoresis
Description: We will administer treprostinil at increasing doses by a iontophoresis.
Study NCT03654989 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Remodulin® placebo iontophoresis
Description: Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~* Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~* Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².
Study NCT04121221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot
Description: Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
Study NCT04121221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM injection once every 4 weeks
Study NCT01551836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol formulation 1
Description: formulation 1
Study NCT01551836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol formulation 2
Description: Formulation 2
Study NCT00950209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saline infusion
Description: In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48
Study NCT03620981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 tablet /day Once daily for 10 weeks
Study NCT04158258 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT04158258 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT04158258 — intervention group
Intervention type: DRUG
Intervention: Ado-trastuzumab emtamsine
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT04158258 — intervention group
Intervention type: DRUG
Intervention: Pertuzumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT04158258 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT04158258 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT00950209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: euglycaemic hyperinsulinic clamp
Description: an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
Study NCT03731000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL® device
Description: Using PHIL® device for treatment of intracranial dural arteriovenous fistulas